Stock Financial Ratios, Dividends, Split History

AXE / Anixter International, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price65.25
Volume136,000.00
Market Cap ($M)2,527.90
Enterprise Value ($M)3,707.40
Book Value ($M)1,491.90
Book Value / Share44.62
Price / Book1.77
NCAV ($M)83.10
NCAV / Share2.49
Price / NCAV26.17
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 33,600,000
Common Stock Shares Outstanding 33,657,466
Weighted Average Number Of Diluted Shares Outstanding 34,000,000
Common Shares Outstanding 33,293,079
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.04
Return on Assets (ROA)0.03
Return on Equity (ROE)0.08
Balance Sheet (mrq) ($M)
Assets4,277.30
Liabilities2,785.40
Quick Ratio1.23
Current Ratio2.21
Income Statement (mra) ($M)
Sales Revenue Net7,927,400,000.00
Operating Income313.10
Net Income109.00
Earnings Per Share Basic3.24
Earnings Per Share Diluted3.21
Cash Flow Statement (mra) ($M)
Cash From Operations183.80
Cash from Investing-41.10
Cash from Financing-41.10
Identifiers and Descriptors
CUSIP035290105
Central Index Key (CIK)52795
Related CUSIPS
003529010 035290905 035290955

Split History

Stock splits are used by Anixter International, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

New Strong Sell Stocks for June 8th

2018-06-08 zacks
AeroCentury Corp. (ACY - Free Report) is an acquirer and leaser of aircrafts and aircraft engines. The Zacks Consensus Estimate for its current year earnings has been revised 34.9% downward over the last 60 days. (134-1)

New Strong Sell Stocks for May 23rd

2018-05-23 zacks
Accuray Incorporated (ARAY - Free Report) is a developer of radiosurgery and radiation therapy systems. The Zacks Consensus Estimate for its current year earnings has been revised 52.6% downward over the last 30 days. (32-0)

New Strong Sell Stocks for May 21st

2018-05-21 zacks
AZZ Inc. (AZZ - Free Report) is a provider of galvanizing services and highly engineered services. The Zacks Consensus Estimate for its current year earnings has been revised 6.5% downward over the last 30 days. (34-1)

Why Earnings Season Could Be Great for Cinemark (CNK)

2018-05-08 zacks
Investors are always looking for stocks that are poised to beat at earnings season Cinemark Holdings, Inc. (CNK - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (21-0)

Should You Buy Banco Macro (BMA) Ahead of Earnings?

2018-05-08 zacks
Investors are always looking for stocks that are poised to beat at earnings season Banco Macro S.A. (BMA - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. (10-0)

CUSIP: 035290105